{
    "nctId": "NCT00386685",
    "briefTitle": "XRP9881 in Combination With Trastuzumab in Metastatic Breast Cancer",
    "officialTitle": "Open Label, Uncontrolled Study of XRP9881 in Combination With Trastuzumab (Herceptin\u00ae) in Patients With HER2 Positive Metastatic Breast Cancer (MBC)",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Neoplasms",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 51,
    "primaryOutcomeMeasure": "Response rate (best overall response under treatment)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Metastatic breast cancer (MBC)\n* HER2 (Human Epidermal Growth Factor Receptor 2) positive: FISH (Fluorescent In Situ Hybridization) positive or IHC (Immunohistochemistry) 3+\n* Measurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST)\n* Adequate organs functions\n\nExclusion Criteria:\n\n* More than one previous chemotherapy regimen for metastatic disease\n* Cardiac dysfunction",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}